Abstract
The case fatality rate in patients suffering a myocardial infarction (MI) is highest within the first 24 hours of onset of symptoms. The majority of these early deaths occur before any medical attention is received either as emergency care or after admission to a hospital. This fact underscores the great potential for primary prevention. The case fatality rate falls over the course of the hospital stay and it continues to decrease over the subsequent 3–6 months. After this critical period, survivors stabilize at a risk of dying 4–8 times that faced by a comparable non-coronary population. This points to the potential value of secondary prevention.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Friedman, L.M., Furberg, C.D., DeMets, D.L.: Fundaments of Clinical Trials. John Wright — PSG Inc., Littleton, Mass, 1981.
May, G.S., Eberlein, K.A., Furberg, C.D., Passamani, E.R., DeMets, D.L.: Secondary prevention after myocardial infarction: A review of long-term trials. Progr. CV Diseases 24:331, 1982.
Collaborative Group: Phenytoin after recovery from myocardial infarction: Controlled trial in 568 patients. Lancet 2: 1055, 1971.
Peter, T., Ross, D., Duffield, A., Luxton, M., Harper, R., Hunt, D., Sloman, G.: Effect on survival after myocardial infarction of long-term treatment with phenytoin. Br. Heart J 40: 1356, 1978.
Rydén, L., Amman, K., Conradson, T.-B., Hofvendahl, S., Mortensen, O., Smedgard, P.: Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocaninide in patients with and recovering from acute myocardial infarction. Am. Heart J 100: 1006, 1980.
Bastian, B.C., McFarland, P.W., McLauchlan, J.H., Ballantyne, D., Clark, R., Hillis, W.S., Rae, A.P., Hutton, I.: A prospective randomized trial of tocainide in patients following myocardial infarction. Am. Heart J 100: 1017, 1980.
Chamberlain, D.A., Jewitt, D.E., Julian, D.G., Campbell, R.W.F., Boyle, D. McC., Shanks, R.G.: Oral mexiletine in high-risk patients after myocardial infarction. Lancet 2: 1324, 1980.
Van Durme, J.P., Hagemeijer, F., Bogaert, M., Glaser, B., Hugenholtz, P.G.: Chronic antidysrhythmic treatment after myocardial infarction. Design of the Gent-Rotterdam Aprindine Study. In Multicenter Controlled Trials: Principles and Problems, edited by Boissel, J.P., Klimt, C.R., Paris, INSERM 76: 43, 1977.
Oliver, M.F., Boyd, G.S.: Influence of reduction of serum lipids on prognosis of coronary heart disease: Five-year study using oestrogen. Lancet 2: 499, 1961.
Stamler, J., Pick, R., Katz, L.N., Pick, A., Kaplan, B.M., Berkson, D.M., Century, D.: Effectiveness of estrogens for therapy of myocardial infarction in middle-age men. JAMA 183: 106, 1963.
Leren, P.: The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. Acta Med. Scand., Suppl. 466: 1966.
Leren, P.: The Oslo Diet-Heart Study: Eleven year report. Circulation 42: 935, 1970.
Controlled trial of soya-bean oil in myocardial infarction: Report of a Research Committee to the Medical Research Council. Lancet 2: 693, 1968.
The Coronary Drug Project Research Group: Initial findings leading to modifications of its research protocol. JAMA 214: 1303, 1970.
The Coronary Drug Project Research Group: Findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA 220: 996, 1972.
The Coronary Drug Project Research Group: Findings leading to discontinuation of the 2.5 mg/day estrogen group. JAMA 226: 652, 1973.
The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 231: 360, 1975.
Detre, K.M., Shaw, L.: Long-term changes of serum cholesterol with cholesterol-altering drugs in patients with coronary heart disease: Veterans Administration Drug-Lipid Cooperative Study. Circulation 50: 998, 1974.
Five-year Study by a Group of Physicians of the Newcastle upon Tyne Region: Trial of Clofibrate in the treatment of ischaemic heart disease. Br. Med. J. 4: 767, 1971.
Report by a Research Committee of the Scottish Society of Physicians: Ischaemic heart disease: A secondary prevention trial using Clofibrate: Br. Med. J. 4: 775, 1971.
Carlson, L.A., Danielson, M., Ekberg, I., Klintemar, B., Rosenhamer, G.: Reduction of myocardial infarction by the combined treatment with Clofibrate and nicotinic acid. Atherosclerosis 28: 81, 1977.
Rosenhamer, G., Carlson, L.A.: Effect of combined clofibrate-nicotinic acid treatment in ischemic heart disease. Atherosclerosis 37: 129, 1980.
An assessment of long-term anticoagulant administration after cardiac infarction: Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. Br. Med. J. 1: 803, 1959.
An assessment of long-term anticoagulant administration after cardiac infarction: Second report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. Br. Med. J. 2: 837, 1964.
Wasserman, A.J., Gutterman, L.A., Yoe, K.B., Kemp, V.E., Richardson, D.W.: Anticoagulants in acute myocardial infarction: the failure of anticoagulants to alter mortality in randomized series. Am. Heart J 71: 43, 1966.
Seaman, A.J., Griswold, H.E., Beaume, R.B., Ritzmann, L.: Long-term anticoagulant prophylaxis after myocardial infarction. N. Engl. J. Med. 281: 115, 1969.
Breddin, K.: Multicenter two-year prospective study on the prevention of secondary myocardial infarction by ASA in comparison with phenprocoumon and placebo. In Multicenter Controlled Trials: Principles and Problems, edited by Boissel, J.P., Klimt, C.R., Paris, INSERM 76: 79, 1977.
Breddin, K., Loew, D., Lechner, K., Überla, K., Walter, E.: Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study. Thromb. Haemostas 40: 225, 1979.
The Sixty Plus Reinfarction Study Research Group: A double-blind trial to assess longterm oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 2: 989, 1980.
Elwood, P.C., Cochrane, A.L., Burt, M.L., Sweetnam, P.M., Williams, G., Welsby, E., Hughes, S.J., Renton, R.: A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. Br. Med. J. 1: 436, 1974.
The Coronary Drug Project Research Group: Aspirin in coronary heart disease. J. Chron. Dis. 29: 625, 1976.
Elwood, P.C., Sweetnam, P.M.: Aspirin and secondary mortality after myocardial infarction. Lancet 2: 1313, 1979.
Aspirin Myocardial Infarction Study Research Group: A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 243: 661, 1980.
The Persantine Aspirin Reinfarction Trial Research Group: Persantine and aspirin in coronary heart disease. Circulation 62: 449, 1980.
The Anturane Reinfarction Trial Research Group: Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. N. Engl. J. Med. 298: 289, 1978.
The Anturane Reinfarction Trial Research Group: Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N. Engl. J. Med. 302: 250, 1980.
Wilhelmsson, C., Vedin, J.A., Wilhelmsen, L., Tibblin, G., Werko, L.: Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet 2: 1157, 1974.
Vedin, A., Wilhelmsson, C., Werko, L.: Chronic alprenolol treatment of patients with acute myocardial infarction after discharge from hospital. Effects on mortality and morbidity. Acta Med. Scand., Suppl. 575: 1975.
Ahlmark, G., Saetre, H., Korsgen, M.: Reduction of sudden deaths after myocardial infarction. Lancet 2: 1563, 1974.
Ahlmark, G., Saetre, H.: Long-term treatment with beta-blockers after myocardial infarction. Europ. J. Clin. Pharmacol 10: 77, 1976.
Barber, J.M., Boyle, D. McD., Chaturvedi, N.C., Singh, N., Walsh, M.J.: Practolol in acute myocardial infarction. Acta Med. Scand., Suppl. 587: 213, 1975.
Multicentre International Study: Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. Br. Med. J. 3: 735, 1975.
Multicentre International Study: Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. Supplementary report. Br. Med. J. 2: 419, 1977.
Andersen, M.P., Bechsgaard, P., Frederiksen, J., Hansen, D.A., Jurgensen, H.J., Nielsen, B., Pedersen, F., Pedersen-Bjergaard, O., Rasmussen, S.L.: Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Lancet 2:865, 1979.
Baber, N.S., Wainwright-Evans, D., Howitt, G., Thomas, M., Wilson, C., Lewis, J.A., Dawes, P.M., Handler, K., Tuson, R.: Multicentre postinfarction trial of propranolol in 49 hospitals in the United Kingdom, Italy and Yugoslavia. Br. Heart J. 44: 96, 1980.
Wilcox, R.G., Roland, J.M., Banks, D.C., Hampton, J.R., Mitchell, J.R.A.: Randomized trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. Br. Med. J. 1: 885, 1980.
The Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 304: 801, 1981.
Sänne, H.: Exercise tolerance and physical training of non-selected patients after myocardial infarction. Acta Med. Scand., Suppl. 551: 1973.
Wilhelmsen, L., Sanne, H., Elmfeldt, D., Grimby, G., Tibblin, G., Wedel, H.: A controlled trial of physical training after myocardial infarction: Effects on risk factors, nonfatal reinfarction and death. Prevent Med. 4: 491, 1975.
Kentala, E.: Physical fitness and feasibility of physical rehabilitation after myocardial infarction in men of working age. Ann. Clin. Res. 4, Suppl. 9, 1972.
Palatsi, I.: Feasibility of physical training after myocardial infarction and its effect on return to work, morbidity and mortality. Acta Med. Scand., Suppl. 599: 1976.
Kallio, V., Hamalainen, H., Hakkila, J., Luurila, O.: Reduction in sudden death by a multifactorial intervention programme after acute myocardial infarction. Lancet 2: 1091, 1979.
Naughton, J.: Exercise and myocardial infarction: The National Exercise and Heart Disease Project: An overview. Proceedings of the Workshop on Physical Conditioning and Rehabilitation, US DHSS, PHS, NIH, 1979.
Shaw, L.W. (for the National Exercise and Heart Disease Project): Effects of a prescribed supervised exercise program on mortality and cardiovascular morbidity in myocardial infarction subjects: A randomized clinical trial. Presented at the 20th Annual Conference on Cardiovascular Disease Epidemiology, San Diego, 1980.
Rechnitzer, P.A., Sangal, S., Cunningham, D.A., Andrew, G., Buck, C., Jones, N.L., Kavanagh, T., Parker, J.O., Shepherd, R.J., Yuhasz, M.S.: A controlled prospective study of the effect of endurance training on the recurrence rate of myocardial infarction: A description of the experimental design. Am. J. Epidemiol 102: 358, 1975.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1983 Westdeutscher Verlag GmbH, Opladen
About this chapter
Cite this chapter
Furberg, C.D., May, G.S., Eberlein, K.A., Passamani, E.R., Demets, D.L. (1983). Secondary Trials After Myocardial Infarction: A Review. In: Clinical Implications of Recent Research Results in Arteriosclerosis. Abhandlungen der Rheinisch-Westfälischen Akademie der Wissenschaften, vol 70. VS Verlag für Sozialwissenschaften, Wiesbaden. https://doi.org/10.1007/978-3-322-98699-3_7
Download citation
DOI: https://doi.org/10.1007/978-3-322-98699-3_7
Publisher Name: VS Verlag für Sozialwissenschaften, Wiesbaden
Print ISBN: 978-3-322-98700-6
Online ISBN: 978-3-322-98699-3
eBook Packages: Springer Book Archive